ES2384134T3 - Uso de productos proteínicos secretados para prevención y tratamiento de enfermedades pancreáticas y/u obesidad y/o síndrome metabólico - Google Patents

Uso de productos proteínicos secretados para prevención y tratamiento de enfermedades pancreáticas y/u obesidad y/o síndrome metabólico Download PDF

Info

Publication number
ES2384134T3
ES2384134T3 ES09163270T ES09163270T ES2384134T3 ES 2384134 T3 ES2384134 T3 ES 2384134T3 ES 09163270 T ES09163270 T ES 09163270T ES 09163270 T ES09163270 T ES 09163270T ES 2384134 T3 ES2384134 T3 ES 2384134T3
Authority
ES
Spain
Prior art keywords
nucleic acid
seq
acid molecule
polypeptide
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES09163270T
Other languages
English (en)
Spanish (es)
Inventor
Daria Onichtchouk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Develogen AG
Original Assignee
Develogen AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Develogen AG filed Critical Develogen AG
Application granted granted Critical
Publication of ES2384134T3 publication Critical patent/ES2384134T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/52—Isomerases (5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
ES09163270T 2004-02-20 2005-02-18 Uso de productos proteínicos secretados para prevención y tratamiento de enfermedades pancreáticas y/u obesidad y/o síndrome metabólico Expired - Lifetime ES2384134T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04003914 2004-02-20
EP04003914 2004-02-20

Publications (1)

Publication Number Publication Date
ES2384134T3 true ES2384134T3 (es) 2012-06-29

Family

ID=34878165

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09163270T Expired - Lifetime ES2384134T3 (es) 2004-02-20 2005-02-18 Uso de productos proteínicos secretados para prevención y tratamiento de enfermedades pancreáticas y/u obesidad y/o síndrome metabólico

Country Status (6)

Country Link
US (2) US20070248579A1 (de)
EP (2) EP1730189A2 (de)
AT (1) ATE549352T1 (de)
DK (1) DK2096120T3 (de)
ES (1) ES2384134T3 (de)
WO (1) WO2005079840A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008092214A1 (en) * 2007-02-02 2008-08-07 Minomic International Limited Biomarkers for diabetes
WO2013102209A1 (en) * 2011-12-30 2013-07-04 Joslin Diabetes Center, Inc. Glypican-4 based compositions and methods for treating and diagnosing insulin resistance
CN103113468B (zh) * 2013-01-17 2014-05-21 中国人民解放军军事医学科学院基础医学研究所 一种抗肿瘤蛋白质
KR102065150B1 (ko) 2018-04-27 2020-01-10 (주)케어젠 이소트레티노인-펩타이드 결합체를 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물
BR112021022682A2 (pt) 2019-05-14 2022-02-22 Provention Bio Inc Métodos e composições para prevenir diabetes do tipo 1
BR112022017718A2 (pt) 2020-03-05 2022-11-16 Diamedica Usa Inc Polipeptídeos de ulinastatina
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
WO2022251253A1 (en) 2021-05-24 2022-12-01 Provention Bio, Inc. Methods for treating type 1 diabetes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US5605662A (en) 1993-11-01 1997-02-25 Nanogen, Inc. Active programmable electronic devices for molecular biological analysis and diagnostics
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US5886029A (en) * 1997-09-05 1999-03-23 Dhaliwal; Kirpal S. Method and composition for treatment of diabetes
WO2001000672A1 (en) * 1999-06-29 2001-01-04 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
US20030170781A1 (en) * 1999-07-01 2003-09-11 Zymogenetics, Inc. Secreted protein zacrp4
WO2002057453A2 (en) * 2000-12-19 2002-07-25 Curagen Corporation Polypetides and nucleic acids encoding same
US20040248156A1 (en) * 2001-12-03 2004-12-09 Tianhua Hu Methods and materials relating to novel C1q domain-containing polypeptides and polynucleotides
AU2003219167A1 (en) * 2002-03-19 2003-09-29 Genset Sa Treatment of metabolic disorders with a tnf receptor family member (fradj and/or cryptic) agonists or antagonists

Also Published As

Publication number Publication date
US20090298771A1 (en) 2009-12-03
DK2096120T3 (da) 2012-07-09
EP1730189A2 (de) 2006-12-13
ATE549352T1 (de) 2012-03-15
EP2096120B1 (de) 2012-03-14
WO2005079840A3 (en) 2006-10-26
EP2096120A3 (de) 2009-12-02
EP2096120A2 (de) 2009-09-02
WO2005079840A2 (en) 2005-09-01
US20070248579A1 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
US20090298771A1 (en) Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
EP1605965B1 (de) Verwendung von mit saposin verwandten proteinen zur prävention und behandlung von adipositas, diabetes und/oder des metabolischen syndroms
EP1644406B1 (de) Verwendung von dg153 sekretierter proteinprodukte zur prevention und behandlung von pankreaserkrankungen und/oder fettleibigkeit und/oder metabolischem syndrom
EP1644027B1 (de) Verwendung von pleiotrophin zur behandlung von bauchspeicheldrüsenkrankheiten, fettsucht und metabolischem syndrom
US8603993B2 (en) Compositions and methods modulating MG29 for the treatment of diabetes
US20060259988A1 (en) Use of dg931 protein for treating diabetes, obesity and metabolic syndrome
EP2135618B1 (de) SF6 zur Verwendung zur Behandlung von Diabetes und/oder Fettleibigkeit, Screeningverfahren für Modulatoren und Kit
WO2004012758A1 (en) Use of tgf beta ig-h3 for preventing and treating obesity, diabetes and/or metabolic syndrome
US20060234930A1 (en) Use of dg008,dg065,dg210 or dg239 secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
US20070110728A1 (en) Method for preventing and treating diabetes using dg119
US20070050856A1 (en) Use of protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
US20060168667A1 (en) Minibrain homologous proteins involved in the regulation of energy homeostasis
US20060154864A1 (en) Transcript factor and an Akt substrate related to transcriptional action of insulin and applications of same
US20080107639A1 (en) Use of a Dg147 Protein Product for Preventing and Treating Metabolic Disorders
JP2006519757A (ja) エネルギー恒常性の調節に関与するタンパク質
US20050272915A1 (en) Skrp, astray, string, vacm associated with metabolic control